期刊文献+

CEA、CA15-3和CA125对乳腺癌的诊断价值以及影响因素探讨 被引量:8

The Diagnosis Value and Correlation Factors of Serum Tumor Markers CEA,CA15-3 and CA125 in Breast Carcinoma
下载PDF
导出
摘要 研究肿瘤标志物CEA、CA15-3和CA125对乳腺癌的诊断价值,并对影响肿瘤标志物阳性率的相关因素进行分析。采用CLIA法测定血清CEA、CA15-3和CA125水平,以CEA>4.8μg/mL、CA15-3>25U/mL、CA125>35U/mL作为诊断阳性标准。乳腺癌组患者59例,乳腺良性组患者69例,对照组65名。结果表明:乳腺癌CEA,CA15-3和CA125水平较对照组和乳腺良性组明显升高(P<0.05)。CA15-3的灵敏度(42.4%)最高,CA125的特异度(89.6%)最高。采用平行联检法,可提高乳腺癌诊断的灵敏度(67.8%)和阴性预测值(85.0%)。而采用系列联检法,可提高特异度(91.0%)和阳性预测值(58.6%)。与乳腺癌肿瘤标志物阳性率显著相关的因素有:肿瘤分期、皮肤改变、淋巴转移、远处转移和P53(P<0.05)。 To explore the diagnosis value of serum tumor markers CEA, CA15-3 and CA125 in breast cancer, and analysis the correlation factors of positive rate of these markers. The serum samples from 59 patients with breast cancer,69 patients with benign breast disorders and 65 normal persons were collected. The serum levels of CEA, CA15-3 and CA125 in these samples were tested by chemiluminescence immunoassay. The levels of CEA 〉 4.8μg/mL, CA15-3 〉 25U/mL and CA125 〉 35U/mL in samples were used as the positive level. The results showed that the serum CEA, CA15-3 and CA125 levels in patients with breast cancer were significantly higher than those in patients with benign breast disorders and normal controls (P 〈0.05). The CA15-3 showed the high- est sensitivity (42.4%) and the CA125 showed the highest specificity (89.6%). The sensitivity (67.8%) and specificity (91.0%) of combined assay of CEA, CA15-3 and CA-125 could be enhanced. The results indicated that the correlation factor related to positive rate of tumor markers in patients with breast cancer may include the tumor stage, change of skin, lymph nodes metastasis, distant metastasis and P53 ( P 〈 0.05).
出处 《标记免疫分析与临床》 CAS 2009年第1期13-15,共3页 Labeled Immunoassays and Clinical Medicine
关键词 乳腺癌 肿瘤标志物 诊断 相关因素 血清 Breast cancer Tumor marker Diagnosis Correlation factor Serum
  • 相关文献

参考文献6

二级参考文献13

  • 1李景运,于翠凤.CEA、CA15-3检测在乳腺癌中应用价值探讨[J].放射免疫学杂志,2004,17(4):327-328. 被引量:8
  • 2万文徽,李吉友.肿瘤标志的临床应用[J].中华医学检验杂志,1997,20(1):49-51. 被引量:180
  • 3Hou M F,Kao Hsiung I Hsueh Ko Hsueh Tsa Chin,1999年,15卷,9期,520页
  • 4张天泽 徐光炜.肿瘤学[M].天津:天津科学技术出版社,1996.1209.
  • 5孙龙安 李龙 林钢 等.医学特种检验与实验室诊断[M].北京:人民军医出版社,2001.159.
  • 6Page DL,Ellis IO,Elston CW.Histologic grading of breast cancerLet's doit (editorial)[J].Am J Clin Pathol,1995,103:123.
  • 7Kuasela.P,Haglund C,Ruberts PJ.Comperison of a new tumor marker CA242 with CA191CA50 and Carcinoembryorni cantigen (CEA) Indiger-tive tract disease[J].Br J Cancer,1991,63(4):636-640.
  • 8Haglund C,Lundin J,Kuusela D,et al.Ca242 a new tumor marker for pancreatic cancer[J].Br J Cancer,1994,70:487.
  • 9Essmann-Seboth D,Fuchs I,Jakesz R,et al.CA153 in the post operative follow up of breast cancer patients.In:Klapdor R,eds.Current tumor diagnosis:application,clinical relevance,research trends[M].New York:W Zuckschwerdt Verlag,1994:158-159.
  • 10Martin A,Corte MD,Alvarez AM,et al.Prognostic value of pre-operative serum CA15-3 levels in breast cancer.Anticancer Res.2006,26(5B):3965.

共引文献92

同被引文献91

引证文献8

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部